The effectiveness and safety of ustekinumab, a monoclonal antibody used to treat autoimmune and inflammatory disorders such as psoriasis and Crohn's disease, can be influenced by genetic variations in the IL12B gene. These variations impact the gene's expression and functionality, affecting how the drug modulates immune response by targeting the cytokines IL-12 and IL-23, which are linked to the IL12B gene.